載入...
S100B and LDH as early prognostic markers for response and overall survival in melanoma patients treated with anti-PD-1 or combined anti-PD-1 plus anti-CTLA-4 antibodies
BACKGROUND: Immunotherapy with PD-1 antibodies has greatly increased prognosis of patients with advanced melanoma. Identifying biomarkers that predict overall survival (OS) and response to immunotherapy is important. METHODS: OS and best overall response according to RECIST version 1.1 were analysed...
Na minha lista:
| 發表在: | Br J Cancer |
|---|---|
| Main Authors: | , , , , |
| 格式: | Artigo |
| 語言: | Inglês |
| 出版: |
Nature Publishing Group UK
2018
|
| 主題: | |
| 在線閱讀: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6070917/ https://ncbi.nlm.nih.gov/pubmed/29950611 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41416-018-0167-x |
| 標簽: |
添加標簽
沒有標簽, 成為第一個標記此記錄!
|